Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia: Choosing therapy based on prognostic markers
Susan O’Brien, MD
Interactive clinical case:
Risk-adapted therapy for CLL: Is it ready for "prime time"?
Susan O’Brien, MD

CME Posttest

Download slide deck

This activity is supported by Allos Therapeutics, Inc; Cephalon, Inc; Genentech BioOncology; and Millennium, the Takeda Oncology Company.